Cargando…

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study

BACKGROUND: Type 2 diabetes is a major risk factor for chronic kidney disease, which substantially increases the risk of cardiovascular disease mortality. This Phase IIb safety study (AleNephro) in patients with stage 3 chronic kidney disease and type 2 diabetes, evaluated the renal effects of alegl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruilope, Luis, Hanefeld, Markolf, Lincoff, A Michael, Viberti, Giancarlo, Meyer-Reigner, Sylvie, Mudie, Nadejda, Wieczorek Kirk, Dominika, Malmberg, Klas, Herz, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364102/ https://www.ncbi.nlm.nih.gov/pubmed/25407798 http://dx.doi.org/10.1186/1471-2369-15-180

Ejemplares similares

Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia
por: Chen, Yan, et al.
Publicado: (2017)

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome
por: Hansen, Barbara C, et al.
Publicado: (2011)

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial
por: Koomen, Jeroen V., et al.
Publicado: (2019)

Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice
por: Boujon, Valérie, et al.
Publicado: (2019)

Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar
por: Grobbee, Esmée J., et al.
Publicado: (2022)

Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors
por: Dietz, Michel, et al.
Publicado: (2012)

A review of glucagon‐like peptide‐1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus
por: Owens, David R., et al.
Publicado: (2017)

Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
por: Hanefeld, Markolf
Publicado: (2007)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial
por: Hanefeld, Markolf, et al.
Publicado: (2013)

The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
por: Drzewoski, Józef, et al.
Publicado: (2021)

The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow‐Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation
por: Menne, Jan, et al.
Publicado: (2014)

Is Hyperglycemia a Cardiovascular Risk Factor?
por: Pistrosch, Frank, et al.
Publicado: (2011)

Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
por: Hanefeld, Markolf, et al.
Publicado: (2013)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)

Synergy between peroxisome proliferator‐activated receptor γ agonist and radiotherapy in cancer
por: Huang, Guodong, et al.
Publicado: (2018)

Shifting the Disease Management Paradigm From Glucose: What are the cons?
por: Hanefeld, Markolf, et al.
Publicado: (2009)

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report
por: Haider, Ahmad, et al.
Publicado: (2019)

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL
por: Hanefeld, Markolf, et al.
Publicado: (2017)

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials
por: Hanefeld, Markolf, et al.
Publicado: (2016)

Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
por: Hanefeld, Markolf, et al.
Publicado: (2020)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis
por: Suzuki, Shugo, et al.
Publicado: (2016)

Peroxisome proliferator-activated receptor γ agonist suppresses mast cell maturation and induces apoptosis
por: Zhang, Yu, et al.
Publicado: (2017)

Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial
por: Ormseth, Michelle J, et al.
Publicado: (2013)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Renal-Protective Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone in ob/ob Mice
por: Li, Ying, et al.
Publicado: (2019)

Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study
por: Hanefeld, Markolf, et al.
Publicado: (2007)

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study
por: Hanefeld, Markolf, et al.
Publicado: (2011)

The metabolic vascular syndrome - guide to an individualized treatment
por: Hanefeld, Markolf, et al.
Publicado: (2016)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress
por: Sekulic-Jablanovic, Marijana, et al.
Publicado: (2017)

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
por: Hasni, Sarfaraz, et al.
Publicado: (2022)

Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin αIIbβ3
por: Watanabe, Naohide, et al.
Publicado: (2008)

CIB1 is an endogenous inhibitor of agonist-induced integrin αIIbβ3 activation
por: Yuan, Weiping, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_uu742v2ba9n1ccqd3j5qnots7f